Surgical Management of Carcinoid Valve Disease-Mechanical versus Tissue Valves Abstract #1041

Introduction: The prosthetic valve of choice in patients with carcinoid valve disease (CVD) remains controversial due to the limited life expectancy of patients with advanced-stage neuroendocrine tumors (NETs) on one hand, and concerns regarding structural valve deterioration (SVD) on the other.
Aim(s): We reviewed the records of 17 patients with right heart failure due to CVD. All patients received somatostatin analogues perioperatively. Data collected included baseline characteristics, procedural profiles and clinical outcomes.
Materials and methods: The primary NET site was ileum 12, lung 2 and stomach, colon, appendix -1 each. Preoperative urine levels of 5-HIAA (61±36 mg/24h) and serum levels of chromogranin A (2926±4057 ng/ml) were 10 and 50 times greater than normal. Twenty two valves were implanted – tricuspid valve (TVR) – 5 (tissue – 4, mechanical - 1), TVR and pulmonary valve (PVR) – 3 (tissue), PVR -1(mechanical), TVR and mitral valve replacement (MVR) – 1(mechanical). 30-day mortality was 11%. Mean follow up was 22±21 months (range 1-81 months). Four patients developed SVD at 12, 14, 15 and 20 months after surgery. Actuarial 4-year survival and freedom from SVD were 23±14% and 43±15%, respectively.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Simona Glasberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#230 Long-term Follow-up of Tissue Valve Prostheses in Carcinoid Heart Disease
Introduction: Development of carcinoid heart disease (CHD) increases morbidity and mortality. Cardiac valve replacement surgery improves functional class, but tissue prosthesis degeneration can occur early in CHD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel S Knight
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#1021 Recurrent Carcinoid Valvulopathy after Bioprosthetic Valve Surgery
Introduction: Carcinoid heart disease (CHD) typically affects right-sided cardiac structures causing leaflet thickening, retraction and valve dysfunction requiring surgery.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Asst. Clin. Prof Jerome S Zacks
#1138 Staged Percutaneous Treatment of Severe Carcinoid Heart Disease by Transfemoral Pulmonary Valve Replacement and Novel Vena Cava Valve Implantation
Introduction: Carcinoid heart disease with severe valve destruction represents the major cause of high morbidity and mortality in patients with carcinoid syndrome.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Laule M, Baur A, Pape U F, ...